Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: A validation of previous 10-year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly by Alehagen, Urban et al.
RESEARCH ARTICLE
Still reduced cardiovascular mortality 12 years
after supplementation with selenium and
coenzyme Q10 for four years: A validation of
previous 10-year follow-up results of a
prospective randomized double-blind
placebo-controlled trial in elderly
Urban Alehagen1☯*, Jan Aaseth2☯, Jan Alexander3☯, Peter Johansson4,5☯
1 Division of Cardiovascular Medicine, Department of Medical and Health Sciences, Linko¨ping University,
Linko¨ping, Sweden, 2 Research Department, Innlandet Hospital Trust and Inland Norway University of
Applied Sciences, Elverum, Norway, 3 Norwegian Institute of Public Health, Oslo, Norway, 4 Department of
Social and Welfare studies, Linko¨ping University, Norrko¨ping, Sweden, 5 Department of Medical and Health
Sciences, Linko¨ping University, Norrko¨ping, Sweden
☯ These authors contributed equally to this work.
* Urban.Alehagen@liu.se
Abstract
Background
Selenium and coenzyme Q10 are both necessary for optimal cell function in the body. The
intake of selenium is low in Europe, and the endogenous production of coenzyme Q10
decreases as age increases. Therefore, an intervention trial using selenium and coenzyme
Q10 for four years as a dietary supplement was performed. The main publication reported
reduced cardiovascular mortality as a result of the intervention. In the present sub-study the
objective was to determine whether reduced cardiovascular (CV) mortality persisted after
12 years, in the supplemented population or in subgroups with diabetes, hypertension,
ischemic heart disease or reduced functional capacity due to impaired cardiac function.
Methods
From a rural municipality in Sweden, four hundred forty-three healthy elderly individuals
were included. All cardiovascular mortality was registered, and no participant was lost to the
follow-up. Based on death certificates and autopsy results, mortality was registered.
Findings
After 12 years a significantly reduced CV mortality could be seen in those supplemented
with selenium and coenzyme Q10, with a CV mortality of 28.1% in the active treatment
group, and 38.7% in the placebo group. A multivariate Cox regression analysis demon-
strated a reduced CV mortality risk in the active treatment group (HR: 0.59; 95%CI 0.42–
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0.81; P = 0.001). In those with ischemic heart disease, diabetes, hypertension and impaired
functional capacity we demonstrated a significantly reduced CV mortality risk.
Conclusions
This is a 12-year follow-up of a group of healthy elderly participants that were supplemented
with selenium and coenzyme Q10 for four years. Even after twelve years we observed a sig-
nificantly reduced risk for CV mortality in this group, as well as in subgroups of patients with
diabetes, hypertension, ischemic heart disease or impaired functional capacity. The results
thus validate the results obtained in the 10-year evaluation.
The protective action was not confined to the intervention period, but persisted during the
follow-up period. The mechanisms behind this effect remain to be fully elucidated, although
various effects on cardiac function, oxidative stress, fibrosis and inflammation have previ-
ously been identified. Since this was a small study, the observations should be regarded as
hypothesis-generating.
Trial registration
Clinicaltrials.gov NCT01443780.
Introduction
Selenium is a trace element that can be found in all living cells[1, 2]. Important selenoproteins
in the body are selenoprotein P, glutathione peroxidases, and thioredoxin reductase, all pro-
tecting against oxidative stress. Increased vascular oxidative stress and endothelial dysfunction
in patients with coronary heart disease have been reported, although the results are conflicting
[3, 4]. In European populations with low dietary selenium intakes as a result of the low sele-
nium content in the soil, biofortification has been regarded as logical[5, 6], as opposed to the
status in the United States where the selenium soil content is generally high. The estimated
serum selenium concentrations in US citizens are generally above 120 μg/L,[7, 8] whereas con-
centrations below 90 μg/L are invariably reported from European countries.[9–13].
Xia et al. demonstrated an interrelationship between selenium and coenzyme Q10 (ubiqui-
none) in the metabolic pathway to the active form of coenzyme Q10 (ubiquinol) [14].
Moreover, an adequate presence of coenzyme Q10 is needed for optimal functioning of seleno-
proteins. Similarly, a deficiency of selenium could influence the ability to obtain adequate con-
centrations of active coenzyme Q10 in cellular compartments. Coenzyme Q10 is a powerful
anti-oxidant protecting against lipid peroxidation[15]. It has been shown that ubiquinone
reduces the inflammatory response [16]. The endogenous production of coenzyme Q10
decreases continually after the age of 20, and the endomyocardial production is reduced to half
at the age of 80 [17]. Thus, elderly people living in geographical areas with low selenium con-
tent in the soil and food may be at increased risk of heart disease and premature death due to a
possible deficiency of these antioxidants. Our research group have recently reported higher
CV mortality in a community population with low plasma selenium concentration [18].
We have previously reported on a dietary supplementation trial with both selenium and
coenzyme Q10 to 443 elderly Swedish community members performed during 2003 until 2010
[19]. The intervention time was four years, and the follow-up after 5.2 years showed signifi-
cantly reduced CV mortality, improved cardiac function as evaluated by echocardiography,
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and a reduced increase of the N-terminal fragment of proBNP (NT-proBNP), a cardiac peptide
biomarker. The long-term effects as seen after ten years have also been reported by our group,
where we still observed a significant reduction of CV mortality, even if the intervention lasted
for only four years[20]. Positive effects could also be seen in some subgroups of the study
population.
The primary aim of the present study was to evaluate possible CV effects of the intervention
in the same population 12 years after the introduction of a four-year period of supplementa-
tion as a way to validate the surprising results from the 10-year evaluation. A secondary aim
was to determine whether positive effects on CV risk could also be seen after 12 years in the
two genders, in those with diabetes, ischemic heart disease (IHD), hypertension and impaired
functional capacity as measured by the New York Heart Association functional Class (NYHA
class).
Materials and methods
The design of the main study has been published elsewhere [19]. In brief, 443 elderly healthy
participants were given dietary supplementation of 200 mg/day of coenzyme Q10 capsules
(Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 μg/day of organic sele-
nium yeast tablets (SelenoPrecise 200 μg, Pharma Nord, Vejle, Denmark), or a similar placebo
during 48 months, and then the interventions was finished. The study supplementation was
taken in addition to regular medication if used. All study medications (active drug and pla-
cebo) not consumed were returned and counted. All participants were examined by one of
three experienced cardiologists. A new clinical history was recorded, and a clinical examina-
tion was performed, including blood pressure, assessment of New York Heart Association
functional class (NYHA class) as well as ECG and echocardiography. Doppler echocardiogra-
phical examinations were performed with the participant in the left lateral position. The ejec-
tion fraction (EF) readings were categorized into four classes with interclass limits placed at
30%, 40% and 50% [21, 22]. Normal systolic function was defined as EF 50%, while severely
impaired systolic function was defined as EF< 30%. The first participant was included in Janu-
ary 2003, and the last participant concluded the study in February 2010.
As the intervention time was unusually long for the main intervention study (48 months)
only 228 participants completed the study; 86 died during the intervention time, and 129
(29.1%) decided not to complete the study. The reasons for the latter have been presented in
detail in the main publication, but the main reason was there were too many tablets to take
[19]. A flowchart of the total follow-up period is presented as Fig 1.
Written, informed consent was obtained from all patients. The study was approved by the
Regional Ethical Committee in Linko¨ping, Sweden and conforms to the ethical guidelines of
the 1975 Declaration of Helsinki. This study was registered at Clinicaltrials.gov, and has the
identifier NCT01443780. As the trial started when registration in Clinicaltrials.gov, or else-
where was optional, the trial was not registered at the start. Registration took place at the time
of publication, when this became obligatory. There is presently no ongoing study from the
research group with the described preparations.
Biochemical analyses
All blood samples were obtained while the patients were at rest in a supine position. The blood
samples were collected in plastic vials containing EDTA (ethylenediamine tetracetic acid). The
vials were placed on ice before chilled centrifugation at 3000g, and then frozen at -70 ˚C. No
sample was thawed more than twice.
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Fig 1. CONSORT flow chart of the study.
https://doi.org/10.1371/journal.pone.0193120.g001
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Mortality
All instances of cardiovascular mortality (CV mortality) were registered. The mortality infor-
mation was obtained from the National Board of Health and Welfare in Sweden, which regis-
ters all deaths of Swedish citizens based on death certificates or autopsy reports. Written,
informed consent was obtained from all patients.
Statistical methods
Descriptive data are presented as percentages. Chi-square tests were used for discrete variables.
All evaluations are performed according to the intention-to-treat principle. Kaplan-Meier
analysis was used to demonstrate CV mortality during the follow-up period. Cox proportional
hazard regression analysis was used to evaluate risk of CV mortality. The independent vari-
ables included in the multivariate model were variables known to be associated with CV mor-
tality: age, male gender, smoking, hypertension, diabetes, IHD, NYHA class III, treatment
with beta blocker, ACE-inhibitor, Hb<120g/L, EF<40% and active treatment with selenium
and coenzyme Q10.
A P-value of<0.05 was considered statistically significant. All data were analyzed using
standard software (Statistica v. 13.2, Dell Inc, Tulsa, OK).
Results
The study population were followed regarding CV mortality during a median follow-up time
of 4233 days (range 348–5275), i.e. about 12 years. In the survival group the median follow-up
time was 4484 days (range 404–5275), and in the CV mortality group a median follow-up time
of 2818 days (range 348–4869) was recorded.
From the basal characteristics it could be seen that the two populations were balanced at the
start of the intervention in all but one variable, use of ACE-inhibitors (15.8% vs 24.3%;
P = 0.03). After 12 years there was no significant difference between the basal characteristics
variables (Table 1).
Upon analyses of the basal characteristics, it could be seen that at the start of the interven-
tion the active treatment group, and the placebo group had the same age (78 years), whereas in
survivors after 12 years the mean age had decreased to 75 years in the active treatment group,
and to 76 years in the placebo group. At the start of the intervention equal proportions of the
two groups had diagnosed diabetes (21%), whereas after 12 years a reduction of the diabetic
proportion could be seen in both groups, though it was more prominent in the placebo group
(Table 1). The numbers with diagnosed hypertension were equal both in the groups at the start
of the intervention, and after 12 years. Regarding IHD, the intervention and placebo groups
were balanced both at the start and after 12 years; however, both groups exhibited a decrease
in the number with IHD after 12 years.
Cardiovascular mortality within 12 years
When evaluating the CV mortality within the 12-year period, we found that those on active
treatment during the intervention had a significantly lower mortality also after 12 years (active
treatment group: 62/221; 28.1%, vs placebo: 86/222; 38.7%; χ2:13.8; P<0.0001). The differences
in CV mortality during the follow-up were also assessed and displayed in a Kaplan-Meier
graph, showing a clear separation of the two groups (Fig 2).
When applying the CV mortality results in univariate Cox regressions, we observed a highly
significant risk reduction resulting from supplementing the participants with selenium and
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coenzyme Q10 for four years, also after 12 years (HR:0.58; 95%CI: 0.42–0.79; P<0.0007).
Applying the data into a multivariate Cox regression model where well-known variables influ-
encing the cardiovascular risk were included, a cardiovascular risk reduction appeared to
remain also after 12 years (HR:0.59; 95%CI: 0.42–0.81: P = 0.001) (Table 2).
Table 1. Population characteristics at inclusion, and after 12 years.
At study start After 12 years
Active p-value Placebo Active p-value Placebo
n 221 222 100 81
Age, mean 78 78 75 76
Males/Females, n 115/106 110/112 42/58 33/48
Smokers, n (%) 21 (9.5) 0.86 20 (9.0) 2 (2.0) 0.27 4 (4.9)
Diabetes, n (%) 47 (21.3) 0.95 48 (21.6) 19 (19.0) 0.60 13 (16.1)
Hypertension, n (%) 158 (71.5) 0.28 168 (75.7) 69 (69.0) 0.84 57 (70.4)
IHD, n (%) 47 (21.3) 0.51 53 (23.9) 13 (13.0) 0.35 7 (8.6)
NYHA class III, n (%) 41 (18.6) 0.49 47 (21.2) 12 (12) 0.46 7 (8.6)
Medical Treatment
ACEI, n (%) 35 (15.8) 0.03 54 (24.3) 10 (10.0) 0.32 12 (14.8)
Beta blockers, n (%) 81 (36.7) 0.40 73 (32.9) 37 (37.0) 0.11 21 (25.9)
Statins, n (%) 45 (20.7) 0.50 51 (23.0) 20 (20.0) 0.97 16 (19.8)
Examinations
Hb<120g/L, n (%) 23 (10.4) 0.39 29 (13.1) 10 (10.0) 0.98 8 (9.9)
EF<40%, n (%) 16 (7.2) 0.87 17 (7.7) 5 (5.0) 0.98 4 (4.9)
Note: ACEI: ACE- inhibitors; EF: Ejection fraction according to echocardiography; IHD: Ischemic heart disease; NYHA: New York Heart Association functional class
https://doi.org/10.1371/journal.pone.0193120.t001
Fig 2. Kaplan-Meier graph illustrating cardiovascular mortality during a follow-up period of 12 years of those
supplemented with selenium and coenzyme Q10 versus placebo for four years on top of regular pharmaceutical
treatment.
https://doi.org/10.1371/journal.pone.0193120.g002
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Subgroup analyses
When analyzing the two genders separately, we found a highly significant difference in CV
mortality between the female intervention and the placebo groups, 20/106, and 46/112, respec-
tively (χ2:12.7; P = 0.0004) after up to 12 years of follow-up. Similarly, in the male group a
trend for difference between the groups was found (active group: 42/115, compared with the
placebo group; 54/110; χ2:3.63; P = 0.057).
In the group with IHD we found a reduced CV mortality risk after supplementation with
selenium and coenzyme Q10, also after 12 years of follow-up, in comparison with those on pla-
cebo (HR: 0.52; 95%CI: 0.30–0.90; P = 0.02) (Fig 3).
For the group with diabetes we also observed a reduced CV mortality risk after 12 years in
the active supplementation group (HR: 0.50; 95%CI: 0.27–0.93; P = 0.03) (Fig 4).
In the group with hypertension, a reduced CV mortality risk reduction could be seen as
well (HR: 0.60; 95%CI: 0.41–0.85; P = 0.005) (Fig 5).
For those with a severe functional impairment due to reduced cardiac function (NYHA
functional class III) a significant reduction of CV mortality risk could be observed (HR: 0.49;
95%CI: 0.27–0.88; P = 0.002) (Fig 6).
If combining those with IHD and those with impaired systolic cardiac function (EF<40%),
a reduced risk for CV death within the 12-year period could be found with an HR of 0.56 (95%
CI: 0.33–0.05; P = 0.03) (Table 3).
In order to further increase the group at CV risk, we combined the groups with hyperten-
sion, IHD and impaired systolic function. In this group, we found a significant risk reduction
with an HR of 0.60 (95%CI: 0.42–0.84; P = 0.004) as a result of the intervention (Table 3).
By adding those with diabetes to the above group, a significant risk reduction was still
observed, with an HR of 0.59 (95%CI: 0.42–0.83; P = 0.003)(Table 3).
Discussion
In an intervention study in 443 elderly healthy persons, selenium and coenzyme Q10 were
given as a combined dietary supplement for four years. After this period no intervention was
Table 2. Cox proportional hazard regression analysis evaluating risk of cardiovascular mortality by supplementa-
tion of selenium and coenzyme Q10 combined in a multivariate model after 12 years of follow-up after 4 years of
intervention to an elderly community population.
Variables Hazard ratio 95%CI P-value
Age 1.16 1.11–1.22 <0.0001
Male gender 1.80 1.30–2.51 <0.0001
Smoking 1.71 1.08–2.71 0.02
Hypertension 1.23 0.85–1.78 0.27
Diabetes 1.30 0.92–1.86 0.14
IHD 1.50 1.02–2.21 0.04
NYHA class 3 2.01 1.45–3.03 <0.0001
Beta blocker 0.85 0.59–1.21 0.37
ACE-inhibitor 1.11 0.76–1.61 0.59
Hb<120g/L 1.04 0.66–1.65 0.85
EF<40% 0.88 0.50–1.55 0.66
Active treatment 0.59 0.42–0.81 0.001
Notes: EF: Ejection fraction; IHD: Ischemic heart disease; NYHA: New York Heart Association functional class; Q4:
4th quartile
https://doi.org/10.1371/journal.pone.0193120.t002
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given, and thus some of the participants have been without the selenium and coenzyme Q10
intervention for ten years. Our results show a continual and significant reduction in CV mor-
tality during the whole follow-up period of 12 years, which also included the eight-year period
after termination of the intervention (Table 4).
Fig 3. Kaplan-Meier graph illustrating cardiovascular mortality in participants with ischemic heart disease
during a follow-up period of 12 years of those supplemented with selenium and coenzyme Q10 versus placebo for
four years on top of regular pharmaceutical treatment.
https://doi.org/10.1371/journal.pone.0193120.g003
Fig 4. Kaplan-Meier graph illustrating cardiovascular mortality in participants with diabetes during a follow-up
period of 12 years of those supplemented with selenium and coenzyme Q10 versus placebo for four years on top
of regular pharmaceutical treatment.
https://doi.org/10.1371/journal.pone.0193120.g004
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This appears clearly from the calculated mortality rates of the active treatment group, in com-
parison with those of the placebo group (Table 5), as we also did in the 10 years evaluation [20].
In Table 5, the figures from official Swedish mortality statistics are also added for compari-
son. The sample size of the present study is relatively small; therefore, the figures should be
Fig 5. Kaplan-Meier graph illustrating cardiovascular mortality in participants with hypertension during a
follow-up period of 12 years of those supplemented with selenium and coenzyme Q10 versus placebo for four
years on top of regular pharmaceutical treatment.
https://doi.org/10.1371/journal.pone.0193120.g005
Fig 6. Kaplan-Meier graph illustrating cardiovascular mortality in participants with NYHA functional class III
during a follow-up period of 12 years of those supplemented with selenium and coenzyme Q10 versus placebo for
four years on top of regular pharmaceutical treatment.
https://doi.org/10.1371/journal.pone.0193120.g006
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interpreted with caution. However, it is striking that the reduction in CV mortality also
remains after 12 years. Even though the reduction in CV risk measured as reduced CV mortal-
ity is still significant, the effect seems somewhat less after 12 years than after ten years [21],
especially in the male group.
This can probably be explained by the fact that ever-existing pathogenic factors catch up
with the positive effects obtained by our intervention. Also, as reported previously, females
have lower levels of coenzyme Q10 than males, presumably explaining why the females
benefited more than males from the supplementation [23].
The CV mortality risk reduction is significant and stable in all the well-known risk popula-
tions, including those with IHD, hypertension or diabetes. Even after combining groups in
order to increase stepwise the size to the subpopulations, the risk reduction is stable and com-
parable to the risk reduction obtained in the separate subgroups, indicating a robust effect
caused by the intervention. It is tempting to speculate that permanent or progressive structural
Table 3. Model testing the effect of intervention after 12 years on risk for cardiovascular mortality in different
groups.
Variable HR p-Value 95%CV
Total study population 0.58 0.0007 0.42–0.70
HT 0.59 0.005 0.41–0.85
IHD 0.52 0.02 0.30–0.90
DM 0.50 0.03 0.27–0.93
NYHA III 0.49 0.02 0.27–0.88
IHD+EF<40% 0.56 0.03 0.33–0.95
IHD+EF<40%+HT 0.60 0.004 0.42–0.84
IHD+EF<40%+HT+DM 0.59 0.003 0.42–0.83
Note: CV: Coefficient of variation; DM: Diabetes; HT: Hypertension; HR: Hazard ratio; IHD: Ischemic heart disease;
NYHA III: New York Heart Association functional class III
https://doi.org/10.1371/journal.pone.0193120.t003
Table 4. Difference in cardiovascular mortality within 5, 10 and 12 years after intervention of selenium and coenzyme Q10 combined or placebo for four years.
Follow-up time Mortality in active treatment group (%) Mortality in placebo group (%) χ2-value P-value
5 years 5.9 12.6 5.97 0.015
10 years 20.8 38.7 17.01 <0.0001
12 years 28.1 45.0 13.78 0.0002
https://doi.org/10.1371/journal.pone.0193120.t004
Table 5. Mortality rate after 5 years, 10 years and 12 years in the active treatment group compared to the placebo group, and to official mortality statistics.
5.2 years of follow-up 10 years of follow-up 12 years of follow-up
All-cause mort rate Cardiovasc mort rate All-cause mort rate Cardiovasc mort rate All-cause mort rate Cardiovasc mort rate
Active group 2433 1130 4427 2079 4542 2327
Placebo group 3115 2423 5400 3870 5993 3754
Reference pop 5794 2144 15,241 6998 15,420 6326
Note: Mortality rate expressed as mortality /100,000/year
Note: Reference group: Official Swedish mortality statistics based on the age group 80–84 in the 5.2 year follow-up, and on the age group 85 years and above in the 10
years follow-up;
 Figures based on statistics from 2014;
 Figures based on statistics from 2016
https://doi.org/10.1371/journal.pone.0193120.t005
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changes took place in the subjects of the placebo group during the interventional four-year
period, explaining the apparent slowing down of CV pathogenesis in the supplemented group.
Selenium-containing enzymes, as well as the coenzyme ubiquinone are strong antioxidants,
both being required in adequate amounts for normal cell function. Positive effects of supple-
mentation of coenzyme Q10 on endothelial function have also been reported [24]. It has been
shown that increased inflammatory activity[25–27], and oxidative stress occur in the elderly
[28], and as one of the effects of the present intervention is to reduce signs of inflammatory
activity [29], and oxidative stress [30], it is tempting to speculate that this effect is partially
responsible for the long-lasting protection obtained in the present study. Moreover, endothe-
lial cells and platelets may be particularly vulnerable to oxidative stress as they are surrounded
by continuous oxygen transport in the circulation, and also exposed to increasing inflamma-
tory burden with age [31, 32].
Furthermore, the persisting effects even eight years after termination of the supplementa-
tion could be related to the unusually long intervention time of four years, which as discussed
above, presumably was paralleled by structural changes in the placebos. The mean plasma con-
centration in this population was 67 μg/L[18]. For full expression of the extracellular seleno-
protein P, a concentration of>90–140 μg/L is needed [33–35], implying that a selenium
deficiency in fact existed before the intervention and during the whole period in the placebo
group. Apparently, the size of the intervention, 200 μg Se/day was enough to give the needed
blood concentration, which has been reported previously [36]. On average, the supplemented
group had an estimated total daily selenium intake of about 235 μg, which is well above the
requirement to optimize selenoprotein P. It was also below a tolerable upper intake level of
300 μg as recommended by the European Food Safety Authority [37] and Nordic Nutrition
Recommendations [38]. In contrast, the population studied in the American SELECT trial had
a basal Se intake of at least 120 μg/d before supplementation; thus, their supplementation of
200 μg Se/d brought them into a marginal or hazardous zone of above 300 μg [39, 40].
The long-lasting effect of the supplementation might also be related to the fact that a major
component of yeast selenium is selenomethionine, which is, at the expense of methionine,
incorporated into non-seleno proteins, which constitute the unspecific selenium pool having a
long elimination half-life [41]. Another partial explanation of the long-lasting effects might be
that the municipality under study developed an increased interest in supplementation with
selenium and coenzyme Q10 after the intervention period, and therefore some of the partici-
pants of the project may have continued to take supplementation. However, if this was the case,
even though it was not investigated in this study, we would expect that the amount randomized
to the placebo group that might have started post-project supplementation by random be
approximately as those that previously belonged to the active treatment group, and as a result
of the post-project supplementation, the difference between the groups should disappear.
The present 12-year evaluation of cardiovascular mortality after four years of intervention
is unique, and should be regarded as a validation of the surprising results from the 10-year
evaluation, and shows that the positive effects of the intervention persist.
Therefore, the hypothesis arising from our results remains that the intervention with sele-
nium and coenzyme Q10 inhibits the pathogenesis of irreversible, presumably structural,
changes preceding cardiovascular events.
Limitations
The presented study has a limited sample size, making the interpretation of the results difficult.
However, the statistical evaluations are extensive due to the many evaluations performed in
the study population, including those previously published.
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The evaluations of the subgroups are even more uncertain as the sample sizes are smaller
compared to the main study group. However, also in this respect we would like to argue that
the different types of statistical methods used all point in the same direction; a reduction of
mortality was obtained by the intervention, confirming the previous suggestions that the opti-
mal selenium intake lies in the range 100–300 μg/d.
In this report the CV mortality within 12 years has been analyzed, a variable that could be
uncertain as it was based mainly on death certificates, and not on autopsy in a majority of the
participants. However, it is likely that the uncertainties in this study are of the same extent as
previous mortality studies that are not based on autopsies only. Hence, in spite of the limita-
tion we think our results provide interesting information.
The limited age span of the analyzed study population also represents a limitation, making
extrapolation of the results to larger populations difficult. However, the fact that the incidences
of CV as well as of other types of disease are higher in an elderly population compared to youn-
ger persons makes the obtained results of this 12-year follow-up even more intriguing.
Conclusion
We present a 12-year analysis of CV mortality in an elderly Swedish population that had been
given supplementation with selenium and coenzyme Q10 as a contribution to their diet for
four years. The present follow-up revealed a reduced CV mortality risk of more than 40%, and
a significant risk reduction in those with hypertension, IHD, impaired cardiac function, and
diabetes. We consider that the presented data, based on small sample sizes, should be regarded
as hypothesis-generating, as the data are both intriguing and surprising.
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